Researchers at the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine have investigated the impact of mesenchymal stem cell exosomes in the treatment of chronic non-healing wounds. These conditions affect 6.5 million people with diabetes and paraplegia in the Unites States alone, at an estimated treatment cost of $25 billion per year.
Mesenchymal stem cell [MSC] exosomes are cell-derived vesicles that exist in biological fluids. The researchers hypothesized that these exosomes could improve the growth and migration of fibroblasts required for the healing of acute and chronic wounds, leading to the growth of new blood vessels. In addition, the investigators observed MSC-exosome-induced changes in growth factor signaling cascades
"Many chronic wounds are unresponsive to existing treatments," says Dr. Badiavas, the lead author. "While past studies have demonstrated that MSCs were capable of healing chronic wounds, … understanding the role of MSC exosomes in repairing wounds is a step towards developing more effective treatment options."
While mesenchymal stem cells are often proposed as sources of new organs and tissue, their ability to address the widespread challenge of wound healing further broadens their application in regenerative and restorative medicine. As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.